#1 Clinical Trials Search in Europe

Flecainide

This article examines the use of flecainide, an antiarrhythmic medication, in various clinical trials for treating cardiac arrhythmias. Flecainide is being studied for conditions like atrial fibrillation, ventricular arrhythmias, and other heart rhythm disorders. The trials aim to assess flecainide’s efficacy, safety, and optimal dosing in different patient populations and clinical scenarios.

Table of Contents

What is Flecainide?

Flecainide is a medication primarily used to treat various heart rhythm disorders. It belongs to a class of drugs called antiarrhythmics, which help regulate the heartbeat. Flecainide is also known by its brand names Tambocor and Flecainide Acetate[7][8]. This medication works by affecting the electrical signals in the heart to maintain a normal rhythm.

Conditions Treated with Flecainide

Flecainide is used to treat several heart-related conditions, including:

  • Atrial Fibrillation (AF): A common heart rhythm disorder where the upper chambers of the heart beat irregularly[1][2]
  • Paroxysmal Atrial Fibrillation (PAF): A type of AF that comes and goes on its own[3]
  • Ventricular Arrhythmias: Abnormal heart rhythms originating from the lower chambers of the heart[4]
  • Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): A rare inherited heart condition that can cause dangerous heart rhythms[8]

How Flecainide Works

Flecainide works by blocking sodium channels in the heart cells. This action slows down the electrical signals that control the heart’s rhythm. By doing so, it helps to:

  • Convert irregular heart rhythms back to normal (called cardioversion)[3]
  • Prevent recurrence of abnormal heart rhythms[1]
  • Reduce the frequency of premature heartbeats (called ectopic beats)[8]

Administration and Dosage

Flecainide can be administered in several ways:

  • Oral tablets: The most common form, usually taken twice daily[8]
  • Intravenous (IV) infusion: Used in hospital settings for rapid treatment[5]
  • Inhaled form: A newer method being studied for quick treatment of sudden AF episodes[3]

The dosage varies depending on the condition being treated and the patient’s response. It’s crucial to take flecainide exactly as prescribed by your doctor.

Effectiveness of Flecainide

Research has shown that flecainide can be effective in:

  • Reducing the frequency of AF episodes[1]
  • Converting recent-onset AF back to normal rhythm[3]
  • Suppressing ventricular arrhythmias in certain heart conditions[4]

However, its effectiveness can vary among individuals, and it may not be suitable for all patients with heart rhythm disorders.

Ongoing Research and Clinical Trials

Several clinical trials are currently exploring new uses and methods of administering flecainide:

  • Using flecainide to prevent AF after certain heart procedures[1]
  • Investigating inhaled flecainide for rapid treatment of sudden AF episodes[3]
  • Studying flecainide’s effectiveness in rare heart conditions like ARVC[8]
  • Comparing flecainide to other treatments for various heart rhythm disorders[6]

Potential Side Effects and Safety Considerations

While flecainide can be effective, it’s important to be aware of potential side effects and safety considerations:

  • Common side effects: These may include dizziness, vision problems, and nausea[1]
  • Proarrhythmic effects: In some cases, flecainide can worsen existing arrhythmias or cause new ones[8]
  • Regular monitoring: Patients on flecainide typically require regular heart monitoring and blood tests[4]
  • Contraindications: Flecainide may not be suitable for patients with certain heart conditions or those taking specific medications[5]

It’s crucial to discuss all potential risks and benefits with your healthcare provider before starting flecainide treatment.

Aspect Details
Conditions Studied Atrial fibrillation, ventricular arrhythmias, Andersen-Tawil syndrome, arrhythmic mitral valve prolapse, Brugada syndrome
Administration Methods Oral tablets, intravenous infusions, inhaled formulation (experimental)
Primary Outcomes Conversion to sinus rhythm, reduction in arrhythmia burden, time to recurrence of arrhythmias
Safety Assessments Monitoring for pro-arrhythmic effects, ECG changes, adverse events
Comparative Studies Flecainide vs. vernakalant, flecainide + beta-blocker vs. beta-blocker alone, flecainide vs. placebo
Special Populations Patients with rare genetic disorders, post-operative patients, early-stage ARVC

FAQ

  • What is flecainide used for in clinical trials? Flecainide is being studied in clinical trials for various heart rhythm disorders, including atrial fibrillation, ventricular arrhythmias, and conditions like Andersen-Tawil syndrome and arrhythmic mitral valve prolapse. It's being tested for its ability to convert abnormal heart rhythms to normal sinus rhythm and prevent recurrences.
  • How is flecainide administered in these trials? Flecainide is administered in different ways depending on the trial. Some studies use oral tablets, while others use intravenous infusions. There's even a trial exploring an inhaled form of flecainide. Dosages and durations of treatment vary across studies.
  • What are some potential benefits of flecainide being investigated? Researchers are investigating if flecainide can effectively convert atrial fibrillation to normal rhythm, reduce the burden of premature ventricular contractions, prevent recurrences of arrhythmias, and improve quality of life for patients with various heart rhythm disorders.
  • Are there any safety concerns being evaluated for flecainide? Yes, the trials are carefully monitoring for potential side effects and safety issues. This includes watching for pro-arrhythmic effects (where the medication might cause new arrhythmias), changes in ECG measurements, and any other adverse events. Some trials are specifically designed to assess the safety profile of flecainide in certain patient populations.
  • How does flecainide compare to other treatments in these trials? Several trials are comparing flecainide to other treatments or placebo. For example, one study is comparing flecainide to vernakalant for atrial fibrillation, while another is assessing flecainide plus a beta-blocker versus beta-blocker alone for ventricular arrhythmias. These comparisons help determine the relative efficacy and safety of flecainide.

Ongoing Clinical Trials on Flecainide

  • Study of drug combination therapy in asymptomatic patients with frequent premature ventricular contractions and normal heart function to prevent left ventricular dysfunction

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Comparison of Carvedilol and Flecainide Treatment in Patients with Idiopathic Ventricular Arrhythmias

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of flecainide alone or with beta-blockers or calcium channel blockers and quinidine for treating ventricular arrhythmias in patients with Andersen-Tawil syndrome and MEPPC

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study on the Effect and Safety of Flecainide and Metoprolol for Patients with Arrhythmic Mitral Valve Prolapse

    Recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway

  • Study on Flecainide to Reduce Risk of Atrial Arrhythmia After Patent Foramen Ovale Closure in Patients

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    France

Glossary

  • Atrial Fibrillation (AF): An irregular and often rapid heart rhythm that can lead to blood clots in the heart. It increases the risk of stroke, heart failure and other heart-related complications.
  • Ventricular Arrhythmia: Abnormal heart rhythms that originate in the lower chambers of the heart (ventricles). These can be potentially life-threatening.
  • Sinus Rhythm: The normal regular rhythm of the heart set by the natural pacemaker called the sinoatrial node.
  • Cardioversion: A medical procedure that restores a normal heart rhythm in people with certain types of abnormal heartbeats (arrhythmias).
  • Electrocardiogram (ECG): A test that records the electrical activity of the heart, used to detect various heart conditions.
  • Premature Ventricular Contractions (PVCs): Extra, abnormal heartbeats that begin in one of the heart's two lower pumping chambers (ventricles).
  • Mitral Valve Prolapse: A condition in which the flaps (leaflets) of the heart's mitral valve bulge into the left atrium during the heart's contraction.
  • Andersen-Tawil Syndrome: A rare genetic disorder characterized by episodes of muscle weakness, changes in heart rhythm, and developmental abnormalities.
  • Brugada Syndrome: A genetic disorder that can cause a dangerous irregular heart rhythm.
  • Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): A type of heart muscle disease that can lead to potentially dangerous heart rhythm problems.

References

  1. https://clinicaltrials.eu/trial/study-on-flecainide-to-reduce-risk-of-atrial-arrhythmia-after-patent-foramen-ovale-closure-in-patients/
  2. https://clinicaltrials.gov/study/NCT06142604
  3. https://clinicaltrials.gov/study/NCT03539302
  4. https://clinicaltrials.gov/study/NCT05631730
  5. https://clinicaltrials.gov/study/NCT02302274
  6. https://clinicaltrials.gov/study/NCT01646281
  7. https://clinicaltrials.eu/trial/study-on-flecainide-and-drug-combination-for-ventricular-arrhythmias-in-patients-with-andersen-tawil-syndrome-and-multifocal-ectopic-purkinje-related-premature-contractions/
  8. https://clinicaltrials.gov/study/NCT03685149